Cover Image
Market Research Report

Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases

Published by BCC Research Product code 258275
Published Content info 236 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases
Published: August 28, 2018 Content info: 236 Pages
Description

Highlights:

The global market for sexually transmitted disease therapeutics reached $52.0 billion in 2018 and should reach nearly $63.0 billion by 2023, at a compound annual growth rate (CAGR) of 3.9% for the period of 2018-2023.

Hepatitis B & C market for sexually transmitted disease therapeutics reached $25.3 billion in 2018 and should reach $30.4 billion by 2023 at a CAGR of 3.7% through 2023.

HIV/AIDS market for sexually transmitted disease therapeutics reached nearly $22.0 billion in 2018 and should reach $27.1 billion by 2023 at a CAGR of 4.3% through 2023.

Report Scope:

This report organizes information from diverse sources into a comprehensive report that includes sections on disease overviews, industry structure, diagnostic kits, treatment interventions, pharmaceutical products, emerging technologies, regulations, reimbursement and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of sexually transmitted disease with base year data of 2017, estimations for 2018 and forecast for 2019-2023 using projections of CAGR. Market data in value terms is provided at global, regional and country levels for disease areas and treatment by drug class. Market data for sexually transmitted disease diagnostics is provided for regional levels, with details on test types.

The report focuses on key sectional assessments for major disease areas such as chlamydia, genital herpes, HIV and hepatitis, among others, and provides detailed analysis of epidemiology, historic and current disease incidence trends, therapeutic interventions and diagnostic overview. It forecasts the global market by drug class for treatment of STDs and discusses market data for antibiotics, antivirals/antiretrovirals and other treatments. Diagnostic test types such as enzyme immunoassays (EIA) and ELISA, PCR, rapid diagnostics and others, are detailed with market data current and forecasts.

Market dynamics such as drivers, restraints and trends are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific, Latin America and the Middle East. The regional overviews provide information on the epidemiology of sexually transmitted disease by country and region and also details market data for each region. The regulatory scenario is discussed for United States, Europe, Japan and China to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe, and Japan to provide an overview to our readers. Pipeline analysis and scenarios are discussed for major disease to provide details on the major pipeline developments. The competitive landscape discusses the major manufacturers involved in the sexually transmitted disease therapeutics market, key developments and product offerings.

Report Includes:

  • 45 data tables and 53 additional tables
  • An overview of the global market for diagnosis and treatments of sexually transmitted diseases
  • Country specific data and analysis for United States, Canada, Mexico, France, Germany, U.K., Spain, China, India, Japan, and Middle East and Africa
  • Coverage of major disease areas, and a detailed analysis of historic and current disease incidence trends
  • Discussion about market dynamics such as drivers, restraints, and trends
  • Information on the regulations for new drug launches and diagnostic kits for United States, Europe, Japan and China
  • Detailed profiles of the major market players, including Abbott Laboratories, AbbVie Inc., Agilent Technologies, Inc., Biomerieux, Inc., Bio-Rad Laboratories Inc., Novartis Ag, Pfizer Inc., Promega Corp., and Thermo Fisher Scientific, Inc.
Table of Contents
Product Code: PHM005D

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Global Market Overview and Trends

  • Overview of Sexually Transmitted Diseases and Definitions
  • Sexually Transmitted Diseases and Pregnancy
  • Screening Programs and Guidelines
    • Mobile HIV Testing in Brazil
  • Benzathine Penicillin Drug Shortage
  • Trends in Global Transmission of STDs
    • Increasing Incidence of STDs
    • STD Awareness and Screening Services
    • Development of Test Kits with High Sensitivity for Low Resource Settings
  • Challenges
    • Underestimating the Risk of Contracting the Disease
    • Social Stigma Associated with STDs
    • Rising Incidence of Antibiotic Resistance
    • Lack of Prenatal Screening for STDs

Chapter 4: Disease Overview

  • Introduction
  • Chlamydia
    • Overview
    • Epidemiology
    • Diagnosis
    • Treatments
  • Genital Herpes
    • Overview
    • Epidemiology
    • Diagnosis
    • Treatments
  • Gonorrhea
    • Overview
    • Epidemiology
    • Diagnosis
    • Treatments
  • Hepatitis A, B and C
    • Overview
    • Epidemiology
    • Diagnosis
    • Treatments
    • Market Size
  • HIV/AIDS
    • Overview
    • Epidemiology
    • Diagnosis
    • Treatments
    • Market Size and Forecast
  • HPV
    • Overview
    • Diagnosis
    • Treatments
  • Syphilis
    • Overview
    • Epidemiology
    • Diagnosis
    • Treatments
  • Others
    • Overview
    • Market Analysis

Chapter 5: STD Diagnosis and Treatment Options

  • Introduction to STD Diagnostics, by Test Type
    • Enzyme Immunoassay (EIA) and ELISA
    • Polymerase Chain Reaction (PCR)
    • Rapid Diagnostics Tests (RDTs)
    • Others
  • Introduction to Treatment by Drug Class
    • Antibiotics/Antibacterial
    • Antiviral/ Antiretrovirals
    • Others

Chapter 6: The North American Market Breakdown

  • Overview of North American Market
    • United States
    • Canada
    • Mexico

Chapter 7: The European Market Breakdown

  • Overview of the European Market
    • Chlamydia
    • United Kingdom
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe

Chapter 8: The Asia-Pacific Market Breakdown

  • Overview of The Asia-Pacific Market
    • Market Analysis
  • Key Trends in STI Prevention
    • Legal Obstructions
    • Social Stigma and Discrimination
  • China
    • Prevention Programs
    • Legal and Punitive Barriers
    • Market Analysis
  • Japan
    • Chlamydia
    • Genital Herpes
    • Gonorrhea
    • Syphilis
    • Market Analysis
  • India
    • Launch of Hepcinat Plus for Hepatitis C in India
    • Aurobindo Pharma Files for Dolutegravir Generic
    • Market Analysis
  • South Korea
    • Market Analysis
  • Rest of Asia-Pacific
    • HIV/AIDS
    • Market Analysis

Chapter 9: Rest of World Market Breakdown

  • The Rest of World Overview
    • South American Market Overview
    • Middle East and Africa Overview

Chapter 10: Regulatory Structure

  • Overview of Regulations
    • United States
    • Europe
    • Japan
    • China
  • Overview of Pricing and Reimbursement
    • United States
    • Europe
    • Japan

Chapter 11: Pipeline Analysis

  • HIV Pipeline Overview
  • List of Drugs in HIV Pipeline
  • Hepatitis C Pipeline Overview
    • Several Drug Combinations Discontinued
  • Gonorrhea Pipeline Overview
  • Late-Stage Pipeline Molecules
    • Doravirine (MK-1439, DOR)
  • Drugs to Gain Marketing Authorization
    • Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
    • Dolutegravir/Lamivudine (ViiV Healthcare)
    • Aikening (albuvirtide for injection) (Frontier Biotechnology Inc.)
    • Elpida (elsulfavirine) (Viriom, Inc.)
    • Isentress HD (Raltegravir) (Merck & Co., Inc.)

Chapter 12: Competitive Landscape and Key Developments

  • Market Structure Analysis
  • Patent Analysis
  • Key Developments
    • Mergers and Acquisitions
    • Development of Innovative Products/Novel Product Launches
    • Agreement, Collaboration and Partnerships

Chapter 13: Company Profiles

  • ABBOTT LABORATORIES
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • ABBVIE INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • AGILENT TECHNOLOGIES, INC.
    • Company Overview
    • Financials
  • BECTON, DICKINSON AND COMPANY
    • Company Overview
    • Product Information
    • Key Developments and Strategies
    • Financials
  • BIOMERIEUX, INC.
    • Company Overview
    • Product Information
  • BIO-RAD LABORATORIES, INC
    • Company Overview
    • Product Information
  • BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    • Company Overview
    • Financials
    • Development and Strategies
  • BRISTOL-MYERS SQUIBB COMPANY
    • Company Overview
    • Product Information
    • Financials
  • CEPHEID INC.
    • Company Overview
  • GILEAD SCIENCES, INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • GLAXOSMITHKLINE PLC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • HOFFMANN-LA ROCHE INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • HOLOGIC INC.
    • Company Overview
    • Product Information
    • Financials
  • JANSSEN PHARMACEUTICALS, INC.
    • Company Overview
    • Product Information
    • Developments and Strategies
    • Financials
  • MERCK & CO., INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • MERIDIAN LIFE SCIENCE INC.
    • Company Overview
    • Product Information
  • NOVARTIS AG
    • Company Overview
    • Product Information
    • Financials
  • PFIZER INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • PROMEGA CORP.
    • Company Overview
  • QIAGEN N.V.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • QUIDEL CORP
    • Company Overview
    • Product Information
  • THERMO FISHER SCIENTIFIC, INC.
    • Company Overview
    • Product Information
    • Financials

Chapter 14: Appendix: Abbreviations

  • Abbreviations

List of Tables

  • Summary Table A: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
  • Summary Table B: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, Through 2023
    • Table 1: Sexually Transmitted Diseases, by Different Pathogens
    • Table 2: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
    • Table 3: Chlamydia Incidence, 2012-2017
    • Table 4: Chlamydia Diagnostic Products, Brand Name and Manufacturer
    • Table 5: Drugs for Chlamydia Treatment
    • Table 6: Global HSV-1 Prevalence, Aged 0-49 years, 2012
    • Table 7: Global HSV-1 Incidence, Aged 0-49 years, 2012
    • Table 8: Genital Herpes Diagnostic Products, Brand Name and Manufacturer
    • Table 9: Gonorrhea Epidemiology, 2012-2017
    • Table 10: Gonorrhea Diagnostic Products, Brand Name and Manufacturer
    • Table 11: Drug for Gonorrhea Treatment
    • Table 12: Hepatitis A Incidence
    • Table 13: Hepatitis B Incidence
    • Table 14: Hepatitis C Incidence
    • Table 15: Hepatitis B and C Diagnostic Products, Brand Name and Manufacturer
    • Table 16: Hepatitis B Medications by Brand Name, Generic Name, Manufacturer, Indication
    • Table 17: Hepatitis C Medications by Brand Name, Generic Name, Manufacturer, Indication
    • Table 18: Global Market for Hepatitis Therapeutics, by Region, Through 2023
    • Table 19: HIV Prognosis
    • Table 20: HIV Incidence
    • Table 21: HIV Incidence
    • Table 22: HIV/AIDS Diagnostic Products, Brand Name and Manufacturer
    • Table 23: HIV Medications by Drug Class, Generic Name, Brand Name
    • Table 24: Global Market for HIV/AIDS Therapeutics, by Region, Through 2023
    • Table 25: HPV Diagnostic Products, Brand Name and Manufacturer
    • Table 26: HPV Vaccines
    • Table 27: Syphilis Incidence
    • Table 28: Infectious Syphilis Incidence, by Country, 2012-2014
    • Table 29: Syphilis Diagnostic Products, Brand Name and Manufacturer
    • Table 30: Drug for Syphilis Treatment
    • Table 31: Trichomonas Vaginalis Diagnostic Assay, Brand Name, Type and Manufacturer
    • Table 32: Bacterial Vaginosis Diagnostic Products, Brand Name and Manufacturer
    • Table 33: Global Market for Other Therapeutics, by Region, Through 2023
    • Table 34: Global Market for Sexually Transmitted Disease Diagnostics, by Region, Through 2023
    • Table 35: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, Through 2023
    • Table 36: Antibacterial Drugs for STD
    • Table 37: Global Market for Antibiotics, by Region, Through 2023
    • Table 38: Global Market for Antiviral/Antiretroviral drugs, by Region, Through 2023
    • Table 39: Global Market for Other Drug Class, by Region, Through 2023
    • Table 40: North American Estimated HBsAG Seroprevalence, 2016
    • Table 41: North American Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
    • Table 42: North American Market for Sexually Transmitted Disease Therapeutics, by Drug Class, Through 2023
    • Table 43: United States Historic and Current Chancroid Trend, Incidence, 1990-2016
    • Table 44: European Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
    • Table 45: European Market for Sexually Transmitted Disease Therapeutics, by Drug Class, Through 2023
    • Table 46: Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
    • Table 47: Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, by Drug Class, Through 2023
    • Table 48: South American, Middle East and Africa HIV/AIDS Epidemiology, 2016
    • Table 49: South American, Middle East & Africa Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
    • Table 50: South American, Middle East & Africa Market for Sexually Transmitted Disease Therapeutics by Drug Class, Through 2023
    • Table 51: South American Estimated HBsAG Seroprevalence, 2016
    • Table 52: Latin America Estimated HCV Prevalence, 2016
    • Table 53: Latin America Estimated HCV Prevalence, 2016
    • Table 54: Preventive Health Services for Adults Covered by Private Plans Without Cost Sharing
    • Table 55: Preventive Health Services for Children Covered by Private Plans Without Cost Sharing
    • Table 56: HIV Pipeline, 2018
    • Table 57: Gonorrhea Pipeline, 2018
    • Table 58: Gilead Sciences, Inc. Leading Products Revenue, 2015-2017
    • Table 59: GlaxoSmithKline Plc. Leading Products Revenue, 2015-2017
    • Table 60: Merck & Co., Inc. Leading Products Revenue, 2015-2017
    • Table 61: Leading Products Revenue, 2015-2017
    • Table 62: Market Share Analysis for Sexually Transmitted Disease Therapeutics
    • Table 63: Key Patents, Manufacturer, Indication, Approval Date and Expiration
    • Table 64: Abbott Laboratories Marketed Products
    • Table 65: Abbott Laboratories Marketed Products, Diagnostics
    • Table 66: Abbott Laboratories Net Revenue, 2015-2017
    • Table 67: AbbVie Inc. Marketed Products
    • Table 68: AbbVie Inc. Net Revenue, 2015-2017
    • Table 69: Agilent Technologies, Inc. Net Revenue, 2015-2017
    • Table 70: Becton, Dickinson and Company Marketed Products
    • Table 71: Biomerieux, Inc. Marketed Products
    • Table 72: Bio-Rad Laboratories Marketed Products
    • Table 73: Boehringer Ingelheim GmbH, Net Revenue, 2014-2016
    • Table 74: Bristol-Myers Squibb Company Marketed Products
    • Table 75: Bristol-Myers Squibb Company Net Revenue, 2014-2016
    • Table 76: Gilead Science Inc. Marketed Products
    • Table 77: Gilead Sciences Inc. Net Revenue, 2014-2016
    • Table 78: GlaxoSmithKline PLC Marketed Products
    • Table 79: ViiV Healthcare Group of Companies Marketed Products
    • Table 80: GlaxoSmithKline PLC Net Revenue, 2014-2016
    • Table 81: Hoffmann-La Roche Inc. Marketed Products
    • Table 82: Hoffmann-La Roche Inc. Net Revenue, 2015-2017
    • Table 83: Hologic, Inc. Marketed Products
    • Table 84: Hologic Inc. Net Revenue, 2015-2017
    • Table 85: Janssen Pharmaceuticals, Inc. Marketed Products
    • Table 86: Johnson & Johnson Inc. Net Revenue, 2014-2016
    • Table 87: Merck & Co. Inc. Marketed Products
    • Table 88: Merck & Co. Inc. Net Revenue, 2014-2016
    • Table 89: Meridian Life Science, Inc. Marketed Products
    • Table 90: Novartis AG Marketed Products
    • Table 91: Novartis AG Net Revenue, 2014-2016
    • Table 92: Pfizer Inc. Marketed Products by Indication
    • Table 93: Pfizer Inc. Net Revenue, 2015-2017
    • Table 94: Qiagen N.V Marketed Products
    • Table 95: Qiagen N.V. Net Revenue, 2015-2017
    • Table 96: Quidel Corp Marketed Products
    • Table 97: Thermo Fisher Scientific, Inc. Marketed Products
    • Table 98: Abbreviations Used in Sexually Transmitted Disease Therapeutics and Diagnostics Market

List of Figures

  • Summary Figure A: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, 2017-2023
  • Summary Figure B: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, 2017-2023
    • Figure 1: Estimated Deaths Owing to Infectious and Parasitic Diseases, 2016
    • Figure 2: Global Historic and Current Gonorrhea Trend, Incidence, in Men, 2012-2014
    • Figure 3: United States Funding Trend, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2017
    • Figure 4: Global Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 5: Global Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018
    • Figure 6: Global Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023
    • Figure 7: Global Historic and Current Chlamydia Trend, Incidence, Women, 2012-2014
    • Figure 8: Global Historic and Current Chlamydia Trend, Incidence, Men, 2012-2014
    • Figure 9: Global Historic and Current Gonorrhea Trend, Incidence, Men, 2012-2014
    • Figure 10: Global Historic and Current Gonorrhea Trend, Incidence, Women, 2012-2014
    • Figure 11: Hepatitis Timeline, 1990-2004
    • Figure 12: Hepatitis Timeline, 2011-2015
    • Figure 13: Hepatitis Timeline, 2015-2017
    • Figure 14: Global Market for Hepatitis Therapeutics, 2017-2023
    • Figure 15: Global Market for Hepatitis, by Region, 2017-2023
    • Figure 16: Global Historic and Current HIV Trend, Prevalence, 2012-2016
    • Figure 17: Estimated HIV Regional Prevalence, 2016
    • Figure 18: Estimated HIV Regional Incidence, 2016
    • Figure 19: Global Market for HIV/AIDS Therapeutics, 2017-2023
    • Figure 20: Global Market for HIV/AIDS Therapeutics, by Region, 2017-2023
    • Figure 21: United States Syphilis Incidence Among Newborns, 2014-2016
    • Figure 22: Global Historic and Current Infectious Syphilis Trend, Incidence, Men, 2012-2014
    • Figure 23: Global Historic and Current Infectious Syphilis Trend, Incidence, Men, 2012-2014
    • Figure 24: Global Market for Other Therapeutics, 2017-2023
    • Figure 25: Global Market for Other Therapeutics, by Region, 2017-2023
    • Figure 26: Global Market for Sexually Transmitted Disease Diagnostics, 2017-2023
    • Figure 27: Global Market for Sexually Transmitted Disease Diagnostics, by Region, 2017-2023
    • Figure 28: Global Market Share for Sexually Transmitted Disease Diagnostics, by Test Type, 2018
    • Figure 29: Global Market Share for Sexually Transmitted Disease Diagnostics, by Test Type, 2023
    • Figure 30: Global Market for Enzyme Immunoassay (EIA) and ELISA Diagnostics, 2017-2023
    • Figure 31: Global Market for PCR Diagnostics, 2017-2023
    • Figure 32: Global Market for Rapid Diagnostic Tests (RDTs) Diagnostics, 2017-2023
    • Figure 33: Global Market for Other Diagnostics, 2017-2023
    • Figure 34: Global Market for Antibiotic Drugs, 2017-2023
    • Figure 35: Global Market for Antibiotic Drugs, by Region, 2017-2023
    • Figure 36: Global Market for Antiviral/Antiretroviral Drugs, 2017-2023
    • Figure 37: Global Market for Antiviral/Antiretroviral Drugs, by Region, 2017-2023
    • Figure 38: Global Market for Other Drug Class, 2017-2023
    • Figure 39: Global Market for Other Drug Class, by Region, 2017-2023
    • Figure 40: North American Market for Sexually Transmitted Therapeutics, 2017-2023
    • Figure 41: North American Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018
    • Figure 42: North American Market for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023
    • Figure 43: North American Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018
    • Figure 44: North American Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023
    • Figure 45: North American Market for Sexually Transmitted Disease Therapeutics, by Country, 2017-2023
    • Figure 46: United States Sexually Transmitted Diseases Incidence, 2016
    • Figure 47: United States Sexually Transmitted Infections, by Sex, 2016
    • Figure 48: United States Historic and Current Syphilis Trend, Incidence, 1990-2016
    • Figure 49: United States Historic and Current Chlamydia Trend, Incidence, 1990-2016
    • Figure 50: United States Historic and Current Gonorrhea Trend, Incidence, 1990-2016
    • Figure 51: United States Historic and Current Hepatitis A Trend, Incidence, 2012-2016
    • Figure 52: United States Historic and Current Acute Hepatitis B Trend, Incidence, 2012-2016
    • Figure 53: United States Historic and Current Hepatitis C Trend, Incidence, 2012-2016
    • Figure 54: United States Historic and Current HIV Trend, Incidence, 2011-2016
    • Figure 55: United States Market for Sexually Transmitted Disease Therapeutics, 2018-2023
    • Figure 56: Canadian Sexually Transmitted Infections, by Sex, 2014
    • Figure 57: Canadian Historic and Current Chlamydia Trend, Incidence, 2005-2014
    • Figure 58: Canadian Historic and Current Gonorrhea Trend, Incidence, by Sex, 2005-2014
    • Figure 59: Canadian Historic and Current Infectious Syphilis Trend, Incidence, 2005-2014
    • Figure 60: Canadian Historic and Current Congenital Syphilis Trend, Incidence, 2005-2014
    • Figure 61: Canadian Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 62: Mexican Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 63: European Historic and Current Chlamydia Trend, Incidence, 2012-2015
    • Figure 64: European Historic and Current AIDS Trend, Incidence, 2007-2011
    • Figure 65: European Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 66: European Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018
    • Figure 67: European Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023
    • Figure 68: European Market for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018
    • Figure 69: European Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023
    • Figure 70: European Market for Sexually Transmitted Disease Therapeutics, by Country, 2017-2023
    • Figure 71: United Kingdom HIV Incidence, Gay and Bisexual Men, 2015 and 2016
    • Figure 72: United Kingdom Historic and Current Gonorrhea Trend, Incidence, 2011-2015
    • Figure 73: United Kingdom Historic and Current Hepatitis B Trend, Incidence, 2012-2016
    • Figure 74: United Kingdom Historic and Current Hepatitis C Trend, Incidence, 2012-2016
    • Figure 75: United Kingdom Market for Sexually Transmitted Disease Therapeutics, 2018-2023
    • Figure 76: German Historic and Current Hepatitis B Trend, Incidence, 2012-2016
    • Figure 77: German Historic and Current Hepatitis C Trend, Incidence, 2012-2016
    • Figure 78: German Market for Sexually Transmitted Disease Therapeutics, 2018-2023
    • Figure 79: French Historic and Current Chlamydia Trend, Incidence, 2011-2015
    • Figure 80: French Historic and Current Gonorrhea Trend, Incidence, 2011-2015
    • Figure 81: French Historic and Current Hepatitis B Trend, Incidence, 2012-2016
    • Figure 82: French Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 83: Spain Historic and Current Chlamydia Trend, Incidence, 2011-2015
    • Figure 84: Spain Historic and Current Gonorrhea Trend, Incidence, 2011-2015
    • Figure 85: Spain Historic and Current Hepatitis B Trend, Incidence, 2012-2016
    • Figure 86: Spain Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 87: Italian Historic and Current Chlamydia Trend, Incidence, 2011-2015
    • Figure 88: Italian Historic and Current Gonorrhea Trend, Incidence, 2011-2015
    • Figure 89: Italian Historic and Current Hepatitis B Trend, Incidence, 2012-2016
    • Figure 90: Italian Historic and Current Hepatitis C Trend, Incidence, 2012-2016
    • Figure 91: Italian Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 92: Denmark Historic and Current Chlamydia Trend, Incidence, 2011-2015
    • Figure 93: The Netherlands Historic and Current Chlamydia Trend, Incidence, 2011-2015
    • Figure 94: Denmark Historic and Current Gonorrhea Trend, Incidence, 2011-2016
    • Figure 95: Ireland Historic and Current Gonorrhea Trend, Incidence, 2011-2015
    • Figure 96: The Netherlands Historic and Current Hepatitis B Trend, Incidence, 2012-2016
    • Figure 97: Sweden Historic and Current Hepatitis B Trend, Incidence, 2012-2016
    • Figure 98: Sweden Historic and Current Hepatitis C Trend, Incidence, 2012-2016
    • Figure 99: Poland Historic and Current Hepatitis C Trend, Incidence, 2012-2016
    • Figure 100: Rest of Europe Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 101: Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 102: Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018
    • Figure 103: Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023
    • Figure 104: Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018
    • Figure 105: Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023
    • Figure 106: Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, by Country, 2017-2023
    • Figure 107: Chinese Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 108: Japanese Historic and Current HIV/AIDS Infections, Incidence, 2001-2016
    • Figure 109: Japanese Historic and Current Chlamydia Trend, Incidence, 2000-2014
    • Figure 110: Japanese Historic and Current Genital Herpes Trend, Incidence, 2000-2014
    • Figure 111: Japanese Historic and Current Gonorrhea Trend, Incidence, 2000-2014
    • Figure 112: Japanese Historic and Current Syphilis Trend, Incidence, 2008-2014
    • Figure 113: Japanese Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 114: Indian Historic and Current HIV Trend, Incidence, 2005-2016
    • Figure 115: Indian Historic and Current HIV Trend, Prevalence, 2005-2016
    • Figure 116: Indian Historic and Current AIDS, Mortality, 2005-2016
    • Figure 117: Indian Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 118: South Korean Historic and Current HIV/AIDS Infections, Incidence, 2001-2016
    • Figure 119: South Korean Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 120: Australia Historic and Current HIV Trend, Incidence, 2012-2014
    • Figure 121: Australia Mode of HIV Transmission, 2015
    • Figure 122: Australia Historic and Current Hepatitis C Trend, Incidence, 2007-2014
    • Figure 123: Australia Historic and Current Hepatitis B Trend, Incidence, 2007-2014
    • Figure 124: Singapore Historic and Current HIV/AIDS Infections, Incidence, 2001-2015
    • Figure 125: Republic of Korea Historic and Current HIV/AIDS Infections, Incidence, 2001-2016
    • Figure 126: Rest of Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 127: HBV Prevalence, by Region, 2015
    • Figure 128: HCV Infection, by Region, 2015
    • Figure 129: HCV Prevalence, by Region, 2015
    • Figure 130: South American, Middle East & Africa Market for Sexually Transmitted Disease Therapeutics, 2017-2023
    • Figure 131: South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018
    • Figure 132: South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023
    • Figure 133: South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018
    • Figure 134: South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023
    • Figure 135: Gilead Sciences, Inc. Antiviral Sales, 2015-2017
    • Figure 136: Abbott Laboratories, Revenue Share, by Region, 2017
    • Figure 137: Abbott Laboratories Revenue Share, by Business Segment, 2017
    • Figure 138: AbbVie Inc. Revenue Share, by Region, 2016
    • Figure 139: Agilent Technologies, Inc. Revenue Share, by Region, 2017
    • Figure 140: Agilent Technologies, Inc. Revenue Share, by Business Segment, 2017
    • Figure 141: Becton, Dickinson and Company Financial Performance, 2013-2017
    • Figure 142: Becton, Dickinson and Company Revenue Share, by Business Segment, 2017
    • Figure 143: Becton, Dickinson and Company Revenue Share, by Region, 2017
    • Figure 144: Boehringer Ingelheim GmbH Revenue Share, by Region, 2016
    • Figure 145: Boehringer Ingelheim GmbH Revenue Share, by Business Segment, 2016
    • Figure 146: Boehringer Ingelheim GmbH R&D Expenditure, 2014-2016
    • Figure 147: Bristol-Myers Squibb Company Revenue Share, by Region, 2016
    • Figure 148: Bristol-Myers Squibb Company Revenue Share, by Business Segment, 2016
    • Figure 149: Gilead Sciences Inc. Revenue Share, by Business Segment, 2016
    • Figure 150: Gilead Sciences Inc. Revenue Share, by Region, 2016
    • Figure 151: GlaxoSmithKline PLC Revenue Share by Business Segment, 2016
    • Figure 152: GlaxoSmithKline PLC Revenue Share, by Region, 2016
    • Figure 153: Hoffmann-La Roche Inc. Revenue Share, by Segment, 2017
    • Figure 154: Hoffmann-La Roche Inc. Revenue Share, by Region, 2017
    • Figure 155: Johnson & Johnson Inc. Revenue Share, by Business Segment, 2016
    • Figure 156: Johnson & Johnson Inc. Revenue Share, by Region, 2016
    • Figure 157: Merck & Co. Inc. Revenue Share, by Business Segment, 2016
    • Figure 158: Merck & Co. Inc. Revenue Share, by Region, 2016
    • Figure 159: Novartis AG Revenue Share, by Region, 2016
    • Figure 160: Novartis AG Revenue Share, by Business Segment, 2016
    • Figure 161: Pfizer Inc. Revenue Share, by Region, 2016
    • Figure 162: Pfizer Inc. Revenue Share by Business Segment, 2016
    • Figure 163: Qiagen N.V Revenue Share, by Region, 2017
    • Figure 164: Qiagen N.V Revenue Share, by Business Segment, 2017
    • Figure 165: Thermo Fisher Scientific, Inc. Revenue Share, by Region, 2016
    • Figure 166: Thermo Fisher Scientific, Inc. Revenue Share, by Business Segment, 2016
Back to Top